Major Autohemotherapy: How MAH Ozone Therapy Works and What to Know
Major autohemotherapy (MAH) is a form of intravenous ozone therapy. A clinician draws a measured amount of your blood, exposes it to a controlled mixture of oxygen and ozone, and returns it to you through a vein. The aim is to spread ozone-derived reactive mediators through the body rather than expose tissue to ozone gas directly, as Lietz-Kijak and colleagues describe in Frontiers in Medicine (2026). Below we cover the procedure, how it differs from EBOO and other ozone routes, what the evidence says, who should not have it, and what to discuss with a physician before you decide.
TL;DR
MAH draws blood, mixes it with a medical oxygen-ozone gas blend, and reinfuses it, usually under gravity, in a single session.
It is simpler and more established than EBOO, which uses a pump and a dialysis-style chamber and is typically done in a longer course.
Reported benefits include anti-inflammatory and immune-modulating effects, but the clinical evidence is mostly small and of low to moderate quality.
Contraindications are real (G6PD deficiency, hyperthyroidism, severe anemia, bleeding disorders, first-trimester pregnancy), so screening comes before treatment.
Talk with a qualified physician about your history, medicines and goals before booking.
Table of Contents
What major autohemotherapy is
Ozone (O3) is a strong oxidant. When it contacts blood, it reacts with biomolecules and forms reactive oxygen species and lipid ozonation products. Those are the mediators researchers believe carry the signal through the body. Lietz-Kijak et al. note that the proposed model rests on adaptive responses to low-to-moderate oxidative stimuli, and that how well this model applies in clinical practice is still uncertain.
“Major” separates this method from “minor” autohemotherapy, which involves a small blood volume treated with ozone and given as an injection. In MAH, a larger volume is handled and returned intravenously. In the research literature you will see it written as MAH, O3-MAH, MAHT or ozone autohaemotherapy. They all point to the same basic idea.
How an MAH session works
Protocols differ between clinics and countries, but the sequence is consistent:
Screening and history. A clinician reviews your medical history, medicines and any lab work. A G6PD check is part of the safety measures recommended in a 2026 review in Clinical and Experimental Rheumatology.
Blood draw. Venous blood is collected into a sterile, ozone-compatible container. In the standard gravity method described by Rowen and colleagues (2022), about 200 mL of blood is treated with an equal volume of ozone gas.
Ozone exposure. The blood is gently mixed with the gas blend. Concentration is set by a medical ozone generator and is measured in micrograms per milliliter.
Reinfusion. The treated blood returns through a vein under gravity. The same 2026 review recommends controlled reinfusion rates of fewer than 50 drops per minute and strict aseptic technique.
Observation. You rest briefly afterward and report how you feel.
The same Rowen paper estimates that a gravity MAH delivers roughly 6,000 to 14,000 micrograms of ozone per treatment, and notes that some ozone may be absorbed by the plastic bag. Exact numbers depend on the concentration, the volume and the equipment.
MAH compared with EBOO, DIV and other ozone routes
People searching for MAH often ask whether EBOO is “basically dialysis.” It borrows the hardware idea, but the purpose and the dose are different. The table summarizes what the published literature describes.
Method | How it works | Notes from the literature |
MAH | Blood is drawn, mixed with ozone gas, and reinfused under gravity | About 200 mL of blood; 6,000 to 14,000 µg of ozone per treatment (Rowen et al., 2022) |
EBOO | A pump moves blood through a dialysis-type chamber where ozone flows countercurrent through a membrane | Early work treated up to 4,800 mL of blood in an hour; Rowen reports 32 to 46 times more ozone than gravity MAH |
DIV | Ozone gas is injected directly into a vein | Described in the same paper as a distinct route |
HBO3 (10-pass) | Blood is treated with ozone under pressure over multiple passes | Up to 140,000 µg for a 10-pass treatment |
The original EBOO protocol, published by Di Paolo and colleagues in 2005, used a seven-week cycle of 14 one-hour sessions. After a session, they measured a 4 to 5 fold rise in thiobarbituric acid reactants without appreciable red cell hemolysis.
More ozone is not automatically better. Higher-dose methods have been studied less than MAH, and to our knowledge, large head-to-head trials comparing them are lacking. That is one reason MAH remains the reference point many clinicians start from.
What the research says about benefits
The most useful way to read the literature is by separating mechanism from clinical outcome.
Mechanism. Laboratory and small human studies point to immunomodulatory and anti-inflammatory effects, as well as activation of antioxidant defense pathways. A 2025 review by Rowen is one of several papers discussing how ozone may interact with these pathways. We cite it here for the mechanism discussion only.
Clinical outcomes. The Frontiers 2026 review states that clinical evidence is mostly small and heterogeneous, and that efficacy has not been conclusively established. That is the honest baseline, and it should shape how you think about any outcome promised to you.
One of the more encouraging studies is a 2024 pilot randomized controlled trial in people with post-acute sequelae of COVID-19. Patients who received O3-MAH on top of conventional therapy showed greater improvements in symptoms, tidal volume, six-minute walk distance and inflammatory markers than those on conventional therapy alone. It is a pilot, so it points toward larger trials rather than ending the question.
For a broader look at how we read the ozone literature, see our article on ozone therapy benefits and what the research shows.
Who tends to ask about MAH
People usually come to us after conventional care has helped but not fully resolved things. Common themes are persistent inflammation, fatigue after infection, joint complaints and interest in preventive care. MAH is not a substitute for the diagnosis and treatment of any of these. It is one tool a physician may consider inside a wider plan that includes labs, nutrition, sleep and medication review.
Safety, side effects and who should not have MAH
Ozone therapy is a medical procedure, and the quality of the setup matters as much as the gas itself.
Contraindications
According to Anthony et al. (2025), ozone therapy is contraindicated in:
first-trimester pregnancy
glucose-6-phosphate dehydrogenase (G6PD) deficiency
hyperthyroidism
severe anemia
active bleeding disorders
If any of these apply to you, or you are not sure, say so at the first visit. G6PD deficiency is often undiagnosed, which is why screening is built into recommended protocols.
Documented adverse events
The literature describes serious problems that stem from poor technique or poor screening. Galassi et al. (2026) report fatal gas embolism and hepatitis C transmission linked to non-standardized blood-handling procedures. A 2026 scoping review lists rare but serious events with ozone autohaemotherapy: hemolysis, renal failure, hyperkalaemia, myocardial infarction, and cerebral gas embolism in patients with a patent foramen ovale.
Bocci, a long-time researcher in the field, argues that past cross-infections came from imperfect sterilization and negligence, not from correctly performed modern ozone therapy. The practical lesson is the same either way: standardized, sterile, closed-system practice with trained staff.
What safe practice looks like
The 2026 recommendations in Clinical and Experimental Rheumatology name four measures:
mandatory G6PD deficiency screening
ozone concentrations kept within 10 to 40 mcg/mL
controlled reinfusion rates under 50 drops per minute
strict aseptic technique
Ask any clinic you consider how it handles each one. Baseline and follow-up bloodwork also helps a physician see how you respond, and a good framework for it is safety lab monitoring that is planned before treatment rather than added afterward.
Questions to settle with a physician first
A consultation should leave you able to answer these:
Is MAH appropriate for my history? Bring a full list of diagnoses, including thyroid disease, anemia, bleeding or clotting problems and any heart condition. If you have ever been told you have a hole in the heart (patent foramen ovale), mention it.
Which labs come first? A G6PD result, a blood count and thyroid testing are reasonable topics to raise.
What dose and volume will be used, and why? The answer should be specific and fit the published ranges.
How is the equipment sterilized or handled? Single-use, sterile components and a documented protocol are what you want to hear about.
How will we know whether it is helping? Agree on symptoms or biomarkers to track and a point to reassess.
How does it fit with my other treatment? Ozone should complement your existing care, not replace medicines your doctors prescribed.
If you have an autoimmune condition, a heart or kidney condition, or you take blood thinners, make sure the physician who treats that condition knows about your plans.
Our perspective
We see ozone therapy as one option inside a larger integrative plan, never as a standalone answer. When someone asks about major autohemotherapy, the first conversation is rarely about the gas. It is about history, labs, medications and what the person hopes to change. The research tells us ozone acts through oxidative signaling and that the clinical evidence is still developing. We take that as a reason to be careful and thorough: screen for contraindications, keep protocols standardized, and measure outcomes so a decision to continue or stop rests on data. That is how our team works across functional medicine, IV therapy and ozone care. Appointments are long enough to talk through the whole picture, and specialists coordinate so the plan makes sense as a whole. For some patients ozone becomes a useful part of it, and for others a different tool fits better. Either way, you should leave knowing why. Dina
Ozone care at Green Circle Wellness
If you are in Chicago, or in Illinois and prefer a virtual first visit, we can start with a conversation about your history and goals. Our team offers ozone therapy as part of an integrative approach that includes personalized testing and individually tailored plans. You can read how we describe it on our ozone therapy page, and see the full list of what we offer on our services page.
If you are still comparing options, our overview of prolozone therapy explains another way ozone is used, and our hydrogen therapy page covers a related approach built around molecular hydrogen.
FAQ
What is major autohemotherapy with ozone?
It is an intravenous ozone treatment in which a measured volume of your blood is drawn, mixed with a controlled oxygen-ozone gas blend, and returned to you through a vein. The goal is to distribute ozone-derived mediators systemically. In the standard gravity method, about 200 mL of blood is treated per session.
Is EBOO basically dialysis?
Not exactly. EBOO uses a pump and a dialysis-type chamber, with ozone flowing through a membrane into the blood. It treats much larger volumes and delivers considerably more ozone than gravity MAH, according to Rowen and colleagues. Its purpose, ozone exposure, differs from kidney dialysis, which clears waste products.
What are the risks of autohemotherapy?
Rare but serious events are described in the literature, including gas embolism, hemolysis and infection linked to poor blood handling. Screening for G6PD deficiency, keeping doses within recommended ranges and using sterile technique are the main safeguards. Discuss your full history with a physician before treatment.
What are the benefits of autohemotherapy?
Researchers report immunomodulatory and anti-inflammatory effects, and one 2024 pilot trial in post-COVID patients showed improvements when MAH was added to standard care. Overall, though, the clinical evidence is small and varied, so outcomes cannot be promised. A physician can help you set realistic goals and track them.
Who should not have MAH?
Ozone therapy is contraindicated in first-trimester pregnancy, G6PD deficiency, hyperthyroidism, severe anemia and active bleeding disorders. A patent foramen ovale is also a concern raised in the safety literature. Your physician should review these before any session.
Sources
Ozone dialysis delivers three or more times the ozone than gravity MAH, Rowen et al. (2022)
Extracorporeal blood oxygenation and ozonation, Di Paolo et al. (2005)
Ozone therapy: Mechanisms and clinical applications, Anthony et al. (2025)
Clinical use of ozone therapy: a critical appraisal, Galassi et al. (2026)
Oxygen-ozone autohaemotherapy in fibromyalgia: safety, Clinical and Experimental Rheumatology (2026)
Recommended
This article is for education only and is not medical advice.
Comments